Franklin Parlapiano Turner & Welch LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,890 shares of the medical instruments supplier's stock after purchasing an additional 1,061 shares during the quarter. Becton, Dickinson and Company comprises about 2.0% of Franklin Parlapiano Turner & Welch LLC's holdings, making the stock its 19th biggest holding. Franklin Parlapiano Turner & Welch LLC's holdings in Becton, Dickinson and Company were worth $7,235,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Charles Schwab Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock valued at $720,089,000 after acquiring an additional 1,317,723 shares during the period. Nordea Investment Management AB lifted its position in Becton, Dickinson and Company by 31.0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock valued at $647,082,000 after purchasing an additional 673,568 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier's stock worth $1,293,635,000 after purchasing an additional 460,440 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $108,243,000. Finally, The Manufacturers Life Insurance Company grew its position in Becton, Dickinson and Company by 62.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier's stock worth $266,974,000 after purchasing an additional 424,487 shares during the period. 86.97% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on BDX shares. StockNews.com downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $283.00.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Price Performance
NYSE:BDX traded up $2.79 during trading hours on Thursday, hitting $249.69. 724,402 shares of the stock traded hands, compared to its average volume of 1,922,272. The company has a market cap of $72.41 billion, a price-to-earnings ratio of 42.05, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $250.91. The stock has a 50 day moving average price of $229.59 and a 200 day moving average price of $233.55. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts' consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company's revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.42 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.42 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.67%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 70.03%.
Becton, Dickinson and Company declared that its board has initiated a share buyback plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.
Insider Buying and Selling
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares of the company's stock, valued at $1,311,211.44. The trade was a 9.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 500 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,844 shares of company stock valued at $2,210,716. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
